Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine alone versus lisdexamfetamine plus topiramate for binge eating disorder
IRCT20230910059396N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in binge eating disorder (BED) comparing Lisdexamfetamine dimesylate alone with Lisdexamfetamine dimesylate plus topiramate (2 arms). Primary endpoints: Binge eating score, Body mass index and 4 more. Started Sep 2023; status: completed.
02
Drugs
lisdexamfetaminetopiramate
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on IRCT20230910059396N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230910059396N1.